Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Salix Pharmaceuticals announces positive results from Phase III IBS-D study

Salix Pharmaceuticals, Ltd. has announced the positive results from TARGET 3, a Phase III study of the efficacy and safety of repeat treatment with rifaximin 550mg three times daily for 14 days in subjects with irritable bowel syndrome with diarrhea, or IBS-D, that previously responded to an initial treatment course of rifaximin and subsequently experienced a recurrence of their IBS-D symptoms.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Stamford Hospital names CEO of SHIP

Stamford Hospital has named Rod Acosta as CEO of the hospital's affiliate physician network, Stamford Health Integrated Practices, or SHIP.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Boston Scientific receives FDA and CE Mark approval for surgical leads

Boston Scientific Corporation, a medical technology company, has received FDA and CE Mark approval for the CoverEdge 32 and CoverEdge X 32 Surgical Leads, which are designed to blanket the spinal cord for pain coverage.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Forendo out-licenses rights for treatment of secondary hypogonadism to Apricus

Forendo Pharma Oy, a drug development company, has entered into a definitive agreement to out-license the US development and commercialization rights for fispemifene, for treatment of men with secondary hypogonadism, to Apricus Biosciences Inc., a biopharmaceutical company.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

RegeneRx to initiate Phase III neurotrophic keratopathy trial

RegeneRx Biopharmaceuticals, Inc., a developer of therapeutic peptide, has announced the initiation of Phase III to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy, or NK.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Royal Philips reports net loss for Q3

Royal Philips, a health and well-being company, has reported that net loss attributable to the shareholders for the third quarter ended September 28, 2014 was E104 million, or E0.11 loss per share, compared to a net income attributable to the shareholders E282 million, or E0.31 per share, for the same quarter ended September 29, 2013.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Regeneron announces encouraging results from diabetic macular edema study

Regeneron Pharmaceuticals,Inc. has announced that in the National Institutes of Health, or NIH, sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study, in patients with diabetic macular edema, or protocol T, EYLEA Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity from baseline at 52 weeks compared to both bevacizumab and ranibizumab injection, the primary endpoint of the study.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Affymetrix licenses technology for HLA typing from genotyping data from Peptide

Affymetrix, Inc., a developer of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets, has exclusively licensed technology from Peptide Groove LLP that enables HLA typing of human samples from genotyping data generated from a variety of assays including the company's Axiom genotyping assays.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Cerus submits Compassionate Use IDE for Ebola convalescent plasma treatment

Cerus Corporation, a biomedical products company, has submitted a clinical protocol to the FDA to make the INTERCEPT Blood System for plasma available under a Compassionate Use Investigational Device Exemption, or IDE, for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy.

Published By MarketLine
22 Oct 2014
NewsWire
NewsWire

Carl Zeiss introduces cataract surgery products

Carl Zeiss Meditec AG, a provider of medical technology solutions, has announced the introduction of the ZEISS Cataract Suite markerless and a nonexclusive commercial collaboration under which Abbott will distribute the ZEISS portfolio of Cataract Surgery Products in the US.

Published By MarketLine
22 Oct 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.